Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.850
0.00 (0.00%)
At close: Dec 20, 2024, 4:00 PM
1.870
+0.020 (1.08%)
After-hours: Dec 20, 2024, 5:41 PM EST
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for TSHA stock have an average target of 6.63, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 258.38% from the current stock price of 1.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for TSHA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +332.43% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +278.38% | Nov 14, 2024 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +224.32% | Nov 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +278.38% | Nov 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +170.27% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
8.42M
from 15.45M
Decreased by -45.49%
Revenue Next Year
5.08M
from 8.42M
Decreased by -39.74%
EPS This Year
-0.39
from -0.96
EPS Next Year
-0.39
from -0.39
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 15.8M | 15.8M | 10.5M | |||
| Avg | 8.4M | 5.1M | 4.8M | |||
| Low | 6.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.9% | 87.0% | 106.9% | |||
| Avg | -45.5% | -39.7% | -4.6% | |||
| Low | -60.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.36 | -0.33 | -0.38 |
| Avg | -0.39 | -0.39 | -0.43 |
| Low | -0.42 | -0.47 | -0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.